Viraj Kariyawasam

Viraj Kariyawasam

Auto-generated profile, based on publicly available information

Viraj Kariyawasam

Department of Gastroenterology, Concord Repatriation General Hospital, Sydney, NSW 2139 Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2020 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
FMFadi H. Mourad
Fadi H. Mourad
JHJana G Hashash
Jana G Hashash
VKViraj C Kariyawasam
Viraj C Kariyawasam
RLRupert W Leong
Rupert W Leong
Despite multiple studies, the role of cytomegalovirus [CMV] infection in exacerbating the severity of inflammation in ulcerative colitis [UC], and its response to treatment, remain debatable. Additionally, the optimal diagnostic tests for CMV infection in the setting of UC relapse, and timing of antiviral treatment initiation, remain unclear. The challenge faced by gastroenterologists is to differentiate between an acute UC flare and true CMV colitis. It seems that the presence of CMV colitis, as defined by the presence of intranuclear or intracellular inclusion bodies on haematoxylin and eosin [H&E] staining and/or positive immunohistochemistry [IHC] assay on histology, is associated with more severe colitis. Patients with CMV infection and acute severe colitis are more resistant to treatment with corticosteroids than non-infected patients. This refractoriness to steroids is related to colonic tissue CMV viral load and number of inclusion bodies [high-grade CMV infection] which may have a pronounced effect on clinical outcomes and colectomy rates. Whereas many studies showed no effect for antiviral treatment on colectomy rates in CMV-infected UC patients, there was a significant difference in colectomy rates of patients with high-grade infection who received anti-viral therapy compared with those who did not receive treatment. It was therefore proposed that high-grade CMV disease indicates that the virus is acting as a pathogen, whereas in those with low-grade CMV disease, the severity of IBD itself is more likely to influence outcome. The different algorithms that have been put forward for the management of patients with UC and concomitant CMV infection are discussed.

27 September 2021 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
NMNikola Mitrev
Nikola Mitrev
HHHin Huang
Hin Huang
BHBarbara Hannah
Barbara Hannah
VKViraj Chandana Kariyawasam
Viraj Chandana Kariyawasam
Background Exclusive enteral nutrition (EEN) is a potentially effective but underused therapy for Crohn’s disease (CD) in adults. It is first-line induction treatment for paediatric patients but remains a second-line or third-line therapy in adults. Objective To analyse the evidence for EEN in adult patients with CD, and summarise this in a narrative review. Methods In April/May 2020 and July 2021, a literature search was performed using the Medical Subject Headings (MeSH) terms: ‘Crohn’s disease’, ‘CD’, ‘inflammatory bowel disease’, ‘IBD’, ‘exclusive enteral nutrition’, ‘enteral nutrition’, ‘EEN’, in PubMed, Scopus, Cochrane. Additional studies were obtained from references of search result articles as well as general reading. Studies with adult patients with CD treated with EEN were selected. 79 articles of relevance were found. Where data in adults were lacking, data from paediatric studies as extrapolated with care. Results EEN in adult patients been shown to improve clinical, biomarker, endoscopic and radiologic measures of disease activity. EEN avoids the potential adverse effects of recurrent corticosteroids for induction such as metabolic derangements and opportunistic infections. EEN has also demonstrated benefits among adult patients with fistulising and stricturing CD. It may avoid surgery in such patients. Preoperative EEN has also been shown to reduce postoperative complications and recurrence. There appears to be benefits in combing EEN with antitumour necrosis factor agents, however, benefits of combination therapy with other biologics are less clear. A major drawback of EEN therapy in adults has been poor compliance. More palatable polymeric formulations improved patient education and dietitian support may overcome this. Evidence in adults is limited to small studies, often with suboptimal control arms and lack of blinding. Larger scale studies with improved study design are needed to confirm these beneficial effects. Conclusion Despite limitations in evidence EEN should be considered in treating adults with CD.

4 May 2019 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
APAviv Pudipeddi
Aviv Pudipeddi
VKViraj Kariyawasam
Viraj Kariyawasam
CHCraig Haifer
Craig Haifer
BBBrandon Baraty
Brandon Baraty
SPSudarshan Paramsothy
Sudarshan Paramsothy
RLRupert Leong
Rupert Leong
Introduction: Medications in treating Crohn’s disease (CD) have evolved over the last two decades, particularly with the use of biologic agents. There are, however, concerns about the safety and adverse events associated with these medications. The authors review the safety profile of immunosuppressive medications used in Crohn’s disease in adult patients. Areas covered: The authors performed a literature search until October 2018 to examine safety data on thiopurines, methotrexate, anti-TNFα agents, vedolizumab and ustekinumab. The authors focused on ‘trial’ and ‘real-world’ data for the biologic agents. Safety in pregnancy and the elderly are also presented. Expert opinion: Available data in CD suggests that immunosuppressive medications are relatively safe, although there are concerns about an elevated risk of serious infections, skin cancer and lymphoma particularly with thiopurines and anti-TNFα agents. Data on vedolizumab and ustekinumab suggests these newer biologic agents are well-tolerated, however longer term data in CD is required to identify risks with extended use. Apart from methotrexate, there appears to be no adverse congenital outcomes with exposure of drugs during pregnancy.

29 December 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
VKViraj C Kariyawasam
Viraj C Kariyawasam
SKShin Kim
Shin Kim
FMFadi H. Mourad
Fadi H. Mourad
CSChristian P Selinger
Christian P Selinger
PKPeter H Katelaris
Peter H Katelaris
RLRupert W Leong
Rupert W Leong
The use of immunomodulators (IMs) is often avoided in elderly patients with inflammatory bowel disease (IBD) due to concerns about complications. Our aim is to compare the use of IMs in elderly and younger patients with Crohn’s disease (CD) or ulcerative colitis (UC) and identify markers that predict their use. In this retrospective cohort study, patients diagnosed with IBD from 1970 to 2009 were recruited from the “Sydney IBD Cohort.” Patients diagnosed at age 60 years old or older and between 16 and old 40 years were classified as “elderly-onset” and “young-onset” respectively. A total of 255 elderly-onset patients (115 CD, 140 UC) and 1244 young-onset patients (657 CD, 587 UC) were recruited. Most elderly-onset patients had colonic CD (61.4%), whereas young-onset patients had predominantly ileocolonic CD (42.8%, P < 0.0001). Left-sided UC was the most common disease localization for both elderly-onset (52.1%) and young-onset patients (42.2%, P = 0.013). The cumulative probability of IM exposure at 5 years post-diagnosis was significantly less in elderly-onset patients compared with young-onset patients for CD (20.0% vs 33.4%, P = 0.0002) and UC (7.8% vs 13.4%, P = 0.0007). Age at diagnosis was not associated with the time to IMs introduction. Charlson Comorbidity Index was shown to delay IM introduction in CD (hazard ratio [HR] 0.863; 95% CI, 0.787–0.946; P = 0.002) and UC (HR 0.807; 95% CI, 0.711–0.917; P = 0.001). Early IM use was associated with reduced need for abdominal and perianal surgery in CD (HR 0.177; 95% CI, 0.089–0.351; P < 0.0001). Comorbidity and not age at diagnosis is associated with IM introduction. Early IM is associated with reduced surgery in both young- and elderly-onset CD but not UC.

10 October 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
RLRupert Leong
Rupert Leong
ASAnthony Sakiris
Anthony Sakiris
AAArteen Arzivian
Arteen Arzivian
JCJohn David Chetwood
John David Chetwood
TCTHANABOON CHAEMSUPAPHAN
THANABOON CHAEMSUPAPHAN
FGFor the Australian IBD Consensus Working Group
For the Australian IBD Consensus Working Group
Background: Given the introduction of new advanced therapies for inflammatory bowel diseases (IBDs), expanded risk mitigation strategies are essential.Aims: To create a comprehensive set of statements on assessment procedures and vaccinations before starting monoclonal antibodies, Janus kinase (JAK) inhibitors or sphingosine‐1‐phosphate (S1P) modulators for IBD.Methods: We examined literature, guidelines and drug product information regarding vaccination and assessment recommendations for initiating advanced IBD therapies. Using a modified Delphi approach, delegates voted anonymously on the acceptability of these statements prior to and following consensus discussion.Results: We developed eight statements on the domains of infectious diseases screening, vaccinations and assessments prior to commencing JAK inhibitors and S1P modulators. Six statements received agreement. Pre‐advanced therapy screening for infectious diseases was established, and the vaccination protocol was revised. Malignancy, cardiovascular and thromboembolic risk assessments are necessary before initiating JAK inhibitors. Those starting S1P modulators need cardiac and ophthalmic assessments.Conclusions: These consensus statements combine vaccination and assessments on the currently available advanced therapies for IBD as a single comprehensive document that may reduce IBD complications associated with use of advanced therapies. Knowledge gaps identified during the consensus process will provide further research opportunities.

26 January 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
JCJohn David Chetwood
John David Chetwood
YKYanna Ko
Yanna Ko
APAviv Pudipeddi
Aviv Pudipeddi
VKViraj Kariyawasam
Viraj Kariyawasam
SPSudarshan Paramsothy
Sudarshan Paramsothy
RLRupert Leong
Rupert Leong
INTRODUCTION: Comparative effectiveness research provides data on the relative benefits and risks between treatments. In Crohn's disease (CD), however, there are few head-to-head studies comparing advanced therapies and none with long-term follow-up. Real-world effectiveness, defined by treatment persistence, obtained from prospective population-based patient cohorts, may help determine the best sequencing and positioning of biological agents. METHODS: We analyzed the prospectively collected population-based Australian national Pharmaceutical Benefits Scheme dispensing data registry (2005–2019) for CD. There is no mandated biological agent prescribing order, and all citizens and permanent residents are eligible for treatment irrespective of insurance status. Propensity score matching was performed to reduce selection bias. RESULTS: There were 2,029 lines of therapy in 1,446 patients (median age 43 years, interquartile range 34–58, 44% male patients) over the 15-year period with 5,618 patient-years of follow-up. Per line of therapy, 915/2,029 (45.1%) patients used adalimumab, 722/2,029 (35.6%) used infliximab, 155/2,029 (7.6%) used vedolizumab, and 237/2,029 (11.7%) used ustekinumab. When used in biological agent–naive patients, there was no difference in persistence between any agent (P > 0.05). Used after first line in biological agent–experienced CD, ustekinumab had significantly better persistence than non-ustekinumab biological agents (P = 0.0018), vs anti–tumor necrosis factor (TNF) alpha therapy (P = 0.006) or vedolizumab (P < 0.001). Ustekinumab persistence was unaffected by prior biological agent exposure (P = 0.51). After anti-TNF use, ustekinumab had superior persistence to an alternative anti-TNF agent (P = 0.033) and to vedolizumab (P = 0.026). Using a propensity score–matched analysis adjusted for age, immunomodulator use, and bio-exposed status, ustekinumab had superior persistence to anti-TNF (P = 0.01). Multivariate predictors of worse persistence were the use of a non-ustekinumab biological agent (adjusted hazard ratio 2.10, P < 0.001), and bio-experienced status (adjusted hazard ratio 1.23, P < 0.001). DISCUSSION: This large national prospective database with nonhierarchical prescribing of biological agents did not identify superior persistence of any agent in bio-naive CD. However, for patients with bio-experienced CD, persistence was greater with ustekinumab.